Differences in AMH assessments between standard and new high sensitivity AMH assays and impact on prediction of IVF outcomes

Abstract

Since women with AMH levels below current limits of detection often still respond to ovulation induction, low limits of currently widely utilized anti-Müllerian hormone (AMH) assays (∼0.16ng/mL) are clinically limiting in women with low functional ovarian reserve (LFOR). We, therefore, assessed whether a mores sensitive AMH assay may improve prediction of treatment outcomes in LFOR.